PTC Inc

Schäffler AG’s Q1 2026 results show steady revenue and EBIT margin growth, with E‑Mobility driving the firm toward its 2028 goal of doubling EBIT and achieving a mid‑single‑digit group margin.

PTC Inc. shares 24‑month Phase II extension data for HD drug votoplam, showing continued safety but no efficacy details—key for investors, regulators, and IT leaders focusing on data integration and compliance in neurodegenerative trials.

PTC India Financial Services’ new risk‑focused board hire and 9.15% put‑option debentures boost governance, investor confidence and set a model for tech‑enabled compliance.

PTC Industries expands with a 4,500‑5,100‑tonne intelligent forging plant, cutting scrap and boosting domestic aerospace supply while showing disciplined debt repayment for investor confidence.

PTC Industries’ new employee‑stock options and trading‑window rules illustrate how robust governance and insider‑trading compliance drive long‑term value for shareholders, while a senior exit at its PTC India Financial Services arm signals a strateg…

PTC India limits insider trading for 48 hrs after earnings—boosting transparency, investor trust and ESG alignment ahead of 2026.

Sanctuary Advisors and Capital Investment Services liquidate $141 M of PTC Inc. shares, signaling a strategic shift in the industrial‑software sector and guiding IT leaders on vendor risk and portfolio resilience.

PTC India Financial Services’ stable credit ratings and strategic shift toward green, renewable and EV infrastructure finance reveal how the firm is reshaping India’s impact‑driven infrastructure future.

PTC’s sale of Kepware and ThingWorx frees $1.1–$1.3 billion for share buy‑backs, boosting EPS and sharpening focus on high‑margin Intelligent Product Lifecycle tools in a $80 bn growing market.

PTC Therapeutics approves equity‑based inducement grants to attract top scientific talent, strengthening its rare‑disorder drug pipeline and shareholder value.